Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | SOD1 | P00441 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | TPMT | P51580 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521815 | 0.83 | ALDH1A1 (0.50) | CYP3A4IDO1CYP2C19ALDH1A1AHR | |
| SCHEMBL16783445 | 0.83 | HCAR1 (0.39) | TSHRCYP3A4ALDH1A1 | |
| SCHEMBL3541751 | 0.83 | RAPGEF4 (0.32) | TSHRMAPTCYP3A4ALDH1A1 | |
| SCHEMBL874186 | 0.83 | EPAS1 (0.38) | — | |
| SCHEMBL14664933 | 0.78 | TSHR (0.42) | TSHRMAPTTP53CYP3A4IDO1 | |
| SCHEMBL4617695 | 0.78 | KCNH2 (0.41) | CYP3A4 | |
| SCHEMBL240715 | 0.74 | WDR5 (0.44) | TSHRCYP2C19ALDH1A1 | |
| SCHEMBL875081 | 0.72 | CHRNB2 (0.46) | MAPT | |
| SCHEMBL10706723 | 0.71 | TSHR (0.57) | TSHRMAPTTP53CYP3A4IDO1 | |
| SCHEMBL98774 | 0.71 | LMNA (0.47) | MAPTCYP3A4IDO1CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149138-A1 | WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE | The Procter & Gamble Company (US) | 2017-04-05 | — | — | EP | claimed |
| WO-2015184209-A1 | WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE | THE PROCTER & GAMBLE COMPANY (US) | 2015-12-03 | — | — | WO | claimed |
| US-20150344817-A1 | WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE | THE PROCTER & GAMBLE COMPANY | 2015-12-03 | — | — | US | claimed |
| WO-2004009752-A1 | ALKALINE LIQUID DETERGENT COMPOSITION | CJ CORPORATION (KR) | 2004-01-29 | — | — | WO | claimed |
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20250359479-A1 | Light Emitting Device | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-11-20 | — | — | US | disclosed |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | disclosed |
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-24 | — | — | US | disclosed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| EP-3897842-B1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2025-01-29 | — | — | EP | disclosed |
| EP-0544488-B1 | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1998-03-11 | — | — | EP | disclosed |
| EP-0802968-A1 | STABILIZATION OF LIQUID ENZYME COMPOSITIONS | NOVO NORDISK A/S (DK) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996036347-A1 | USE OF LEUKOTRIENE ANTAGONISTS FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0743064-A1 | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease | ELI LILLY AND COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1996021716-A1 | STABILIZATION OF LIQUID ENZYME COMPOSITIONS | NOVO NORDISK A/S (DK) | 1996-07-18 | — | — | WO | disclosed |
| US-5462954-A | Antiinflammatory, antiallergens; treating asthma | ELI LILLY AND COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | TSHR 2806/4885MAPT 3253/4885TP53 4664/4885 |
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | TBXA2R, PIGS, CYCS | TSHR 3891/4885MAPT 4735/4885TP53 4879/4885 |
| US-20250359479-A1 | Light Emitting Device | CRY1, LAGE3, CRY2 | TSHR 3414/4885MAPT 1799/4885TP53 4752/4885 |
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | RECQL, QTRT2, NQO2 | TSHR 2519/4885MAPT 3341/4885TP53 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.